Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials

Joint models for longitudinal and survival data have now become increasingly popular in clinical trials or other studies for assessing a treatment effect while accounting for longitudinal measures such as patient-reported outcomes or tumor response. Most studies in the existing literature primarily focus on reducing the bias and improving efficiency in the estimate of the treatment effect in the joint modeling of survival and longitudinal data. Global fit indices such as Akaike information criterion (AIC) or Bayesian information criterion (BIC) can be used to assess the overall fit of the joint model. However, these indices do not provide separate assessments of each component of the joint model. In this chapter, we develop new model assessment criteria using a novel decomposition of AIC and BIC (i.e., AIC = AIC\(_\textrm{Surv}\) + AIC\(_\textrm{Long} | \textrm{Surv}\) and BIC = BIC\(_\textrm{Surv}\) + BIC\(_\textrm{Long} | \textrm{Surv}\)) to assess the contribution of the survival data to the model fit of the longitudinal data. We apply the proposed methodology to the analysis of a real dataset from a cancer clinical trial in mesothelioma.

[1]  Hongtu Zhu,et al.  Bayesian Influence Measures for Joint Models for Longitudinal and Survival Data , 2012, Biometrics.

[2]  E. Eisenhauer,et al.  Progression-free survival: meaningful or simply measurable? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  V. DeGruttola,et al.  Models for empirical Bayes estimators of longitudinal CD4 counts. , 1996, Statistics in medicine.

[5]  Joseph G. Ibrahim,et al.  A new joint model for longitudinal and survival data with a cure fraction , 2004 .

[6]  Ping Wang,et al.  Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial , 2012, Health Services and Outcomes Research Methodology.

[7]  V. De Gruttola,et al.  Modelling progression of CD4-lymphocyte count and its relationship to survival time. , 1994, Biometrics.

[8]  J. Ibrahim,et al.  Handbook of survival analysis , 2014 .

[9]  Bradley P. Carlin,et al.  Multilevel Bayesian Models for Survival Times and Longitudinal Patient-Reported Outcomes With Many Zeros , 2012 .

[10]  James J. Rusthoven,et al.  Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso , 2005, Supportive Care in Cancer.

[11]  Pennifer Erickson,et al.  Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[12]  Joseph G. Ibrahim,et al.  Bayesian Survival Analysis , 2004 .

[13]  Wei Shen,et al.  Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials , 2014, Statistics in medicine.

[14]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[15]  Joseph G Ibrahim,et al.  Sample size and power determination in joint modeling of longitudinal and survival data , 2011, Statistics in medicine.

[16]  H. Akaike,et al.  Information Theory and an Extension of the Maximum Likelihood Principle , 1973 .

[17]  M. Kris,et al.  A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. , 1997, Lung cancer.

[18]  Joseph G Ibrahim,et al.  Bayesian Approaches to Joint Cure‐Rate and Longitudinal Models with Applications to Cancer Vaccine Trials , 2003, Biometrics.

[19]  J. Ibrahim,et al.  A Bayesian semiparametric joint hierarchical model for longitudinal and survival data. , 2003, Biometrics.

[20]  Yudi Pawitan,et al.  Modeling Disease Marker Processes in AIDS , 1993 .

[21]  Joseph G Ibrahim,et al.  Basic concepts and methods for joint models of longitudinal and survival data. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Hsieh,et al.  Joint Modeling of Survival and Longitudinal Data: Likelihood Approach Revisited , 2006, Biometrics.

[23]  Joseph G. Ibrahim,et al.  BAYESIAN METHODS FOR JOINT MODELING OF LONGITUDINAL AND SURVIVAL DATA WITH APPLICATIONS TO CANCER VACCINE TRIALS , 2004 .

[24]  Bradley P Carlin,et al.  Joint Modeling of Multiple Longitudinal Patient-Reported Outcomes and Survival , 2011, Journal of biopharmaceutical statistics.